MAPT and early-onset autosomal dominant Alzheimer disease: Thiamet-G, a newly developed OGA inhibitor, has been shown to slow progression of Alzheimer's disease by an increase in tau O-GlcNAcylation and the reciprocal decrease in tau phosphorylation and aggregation (57).